Johnson & Johnson

“Raised $85M Series C led by Johnson & Johnson; represents growing institutional pharma interest in psychedelic-adjacent therapeutics without the regulatory complexity of hallucinogens.”

“Delix Therapeutics, a Boston-based developer of psychoplastogens, raised $85m in Series C funding led by J&J.”

“Johnson & Johnson is investing $785m into Sail Biomedicines, a Cambridge, Mass.-based CAR-T cell therapy developer formed by Flagship Pioneering, via a deal that also gives J&J an acquisition option.”